Full IPO calendar HERE
Ranked by IPO size
(1) Based in Maranello (MO) Italy, Ferrari N.V. (RACE) scheduled an $859 million IPO on NYSE with a market capitalization of $9.4 billion at a price range midpoint of $50 for Wednesday, Oct. 21, 2015.
Ferrari is among the world’s leading luxury brands focused on the design, engineering, production and sale of the world’s most recognizable luxury performance sports cars.
RACE’s brand symbolizes luxury, exclusivity.
(2) Based in New York, NY, Multi Packaging Solutions International (MPSX) scheduled a $300 million IPO on NYSE with a market capitalization of $1.2 billion at a price range midpoint of $16 for Thursday, Oct. 22, 2015.
MPSX is a leading, global provider of value-added specialty packaging solutions, based on sales, focused on high complexity products for the consumer, healthcare and multi-media markets.
For the fiscal year ended June 30, 2015, approximately 47%, 47% and 6% of MPSX’s acquisition adjusted pro forma net sales came from its North American, European and Asian operations, respectively, and approximately 87% of its acquisition adjusted pro forma global net sales were derived from its consumer and healthcare end markets.
(3) Based in Cambridge, MA, Dimension Therapeutics (DMTX) scheduled an $83 million IPO on Nasdaq with a market capitalization of $373 million at a price range midpoint of $15 for Thursday, October 22, 2015.
DMTX is a leading gene therapy platform company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations.
DMTX’s initial programs address hemophilia B, hemophilia A, ornithine transcarbamylase, or OTC, deficiency, and glycogen storage disease type Ia, or GSDIa.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer